Acquisitions - Purchase Price Consideration (Details) - Reata Pharmaceuticals, Inc $ / shares in Units, shares in Millions, $ in Millions |
Sep. 26, 2023
USD ($)
$ / shares
shares
|
|---|---|
| Business Acquisition [Line Items] | |
| Total transaction value | $ 6,602.9 |
| Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services | 590.5 |
| Consideration transferred | $ 7,193.4 |
| Price per share | $ / shares | $ 172.50 |
| Number of common stock shares acquired | shares | 38.3 |
| X | ||||||||||
- Definition Business Acquisition, Number of Common Stock Shares Acquired No definition available.
|
| X | ||||||||||
- Definition Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|